FDA accepts Genentech ’s sBLA for gazyva to treat untreated follicular lymphoma

The US Food and Drug Administration (FDA) has accepted biotechnology company Genentech ’s supplemental biologics licence application (sBLA) and granted priority review for gazyva (obinutuzumab) for the treatment of untreated follicular lymphoma.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news